Compare AbbVie Inc (ABBV) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Invesco NASDAQ 100 ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Invesco NASDAQ 100 ETF trades at $292.64. The key difference: AbbVie Inc pays a 2.72% dividend while Invesco NASDAQ 100 ETF pays none. Which is the better fit depends on your goals.
| ABBV | QQQM | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $307.23 |
52-Week Low | $184.85 | $227.35 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
QQQM trades at $297.52, up 1.4% with bullish technical signals from moving averages. The ETF benefits from SpaceX's imminent Nasdaq-100 inclusion on July 7, 2026, expected to bring modest 1% weighting. Technical analysis shows support at $296 and resistance at $299, with overall bullish momentum supported by 12 buy signals versus 4 sell signals.
The outlook remains positive with AI-driven growth exposure and new index additions. Risks include concentration in large-cap tech and market volatility. Analyst sentiment favors long-term holding given the ETF's cost efficiency and growth potential in technology sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
